Mcmillion Capital Management Inc. raised its stake in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 4.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,512 shares of the financial services provider’s stock after purchasing an additional 976 shares during the period. Mcmillion Capital Management Inc.’s holdings in iShares Nasdaq Biotechnology ETF were worth $2,364,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of IBB. Parkside Financial Bank & Trust bought a new position in shares of iShares Nasdaq Biotechnology ETF during the 4th quarter worth about $29,000. Intercontinental Wealth Advisors LLC bought a new position in shares of iShares Nasdaq Biotechnology ETF during the 4th quarter worth about $56,000. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of iShares Nasdaq Biotechnology ETF by 636.4% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 891 shares of the financial services provider’s stock worth $109,000 after acquiring an additional 770 shares during the period. Schroder Investment Management Group bought a new position in shares of iShares Nasdaq Biotechnology ETF during the 2nd quarter worth about $105,000. Finally, North Star Investment Management Corp. lifted its holdings in shares of iShares Nasdaq Biotechnology ETF by 21.6% during the 4th quarter. North Star Investment Management Corp. now owns 1,180 shares of the financial services provider’s stock worth $114,000 after acquiring an additional 210 shares during the period. 66.51% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:IBB opened at $112.04 on Monday. iShares Nasdaq Biotechnology ETF has a 52 week low of $89.01 and a 52 week high of $122.97.

TRADEMARK VIOLATION WARNING: This report was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://theolympiareport.com/2019/02/18/mcmillion-capital-management-inc-raises-holdings-in-ishares-nasdaq-biotechnology-etf-ibb.html.

About iShares Nasdaq Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More: Calculating net profit and net profit margin ratio

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.